This updated guideline is in draft form for consultation. It includes
a number of potential new recommendations on issues including; when to
offer genetic testing; what surveillance strategies should and should
not be offered; and the use of tamoxifen or raloxifene as treatments to
prevent breast cancer. Registered stakeholders are invited to comment on
the provisional recommendations until the 25th February 2013.
